Threshold Pharmaceuticals Inc. (NASDAQ:THLD) has received a consensus rating of “Hold” from the five research firms that are presently covering the firm. Three investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $0.52.
Several brokerages recently weighed in on THLD. S&P Equity Research cut their price objective on shares of Threshold Pharmaceuticals from $0.67 to $0.52 in a report on Friday, September 30th. William Blair restated an “outperform” rating on shares of Threshold Pharmaceuticals in a report on Monday.
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.5674 on Tuesday. Threshold Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $4.44. The firm has a market cap of $40.58 million, a price-to-earnings ratio of 0.9584 and a beta of 3.97. The company has a 50 day moving average of $1.04 and a 200 day moving average of $0.62.
Threshold Pharmaceuticals (NASDAQ:THLD) last announced its quarterly earnings data on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). On average, equities analysts forecast that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. Oxford Asset Management raised its stake in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the period. Paloma Partners Management Co purchased a new stake in Threshold Pharmaceuticals during the second quarter valued at $152,000. Renaissance Technologies LLC raised its stake in Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 363,100 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares during the period. Finally, Deerfield Management Co. purchased a new stake in Threshold Pharmaceuticals during the second quarter valued at $1,641,000. Institutional investors own 28.22% of the company’s stock.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.